India: CDSCO Status and the Domestic Generics Question
India's patent and regulatory landscape has made it an early test case for lower-cost GLP-1 competition, subject to its own approval and patent rules.
By the GLP Semaglutide editorial team · Last updated February 8, 2026
India's Central Drugs Standard Control Organisation (CDSCO) is the national regulator responsible for drug approvals, including GLP-1 receptor agonists marketed in the country by both multinational manufacturers and domestic pharmaceutical companies.
A different patent landscape
India's patent law and its history of compulsory licensing provisions have made it a market where domestic manufacturers have moved relatively early toward developing lower-cost versions of some GLP-1 molecules, subject to the specific patent status of each product in India.
Quality verification still applies
A CDSCO-approved, licensed-pharmacy product is a different thing from an unverified online listing claiming Indian manufacture — the same sourcing caution that applies globally to unregulated 'research peptide' sellers applies here too.
Primary sources